Kabataş Serdar, Civelek Erdinç, Kaplan Necati, Savrunlu Eyüp Can, Sezen Gülseli Berivan, Chasan Mourat, Can Halil, Genç Ali, Akyuva Yener, Boyalı Osman, Diren Furkan, Karaoz Erdal
Department of Neurosurgery, University of Health Sciences, Gaziosmanpaşa Training and Research Hospital, İstanbul 34255, Turkey.
Department of Neurosurgery, Istanbul Rumeli University, Çorlu Reyap Hospital, Tekirdağ 59860, Turkey.
World J Exp Med. 2021 Mar 20;11(2):17-29. doi: 10.5493/wjem.v11.i2.17.
Hypoxic-ischemic encephalopathy (HIE) is a leading cause of morbidity and mortality in the adult as well as in the neonate, with limited options for treatment and significant dysfunctionality.
To investigate the safety and preliminary efficacy of allogeneic mesenchymal stem cells (MSCs) in HIE patients.
Patients who had HIE for at least 6 mo along with significant dysfunction and disability were included. All patients were given Wharton's jelly-derived MSCs at 1 × 10/kg intrathecally, intravenously, and intramuscularly twice a month for two months. The therapeutic effects and prognostic implications of MSCs were evaluated by multiple follow-ups. Functional independence measure (FIM), modified Ashworth, and Karnofsky scales were used to assess any side effects, neurological and cognitive functions, and overall outcomes.
The 8 subjects included in the study had a mean age of 33.25 ± 10.18 years. Mean HIE exposure and mean post-HIE durations were 45.63 ± 10.18 and 19.67 ± 29.04 mo, respectively. Mean FIM score was 18.38 ± 1.06, mean modified Ashworth score was 43.5 ± 4.63, and mean Karnofsky score was 20. For the first 24 h, 5 of the patients experienced a subfebrile state, accompanied by mild headaches due to intrathecally administration and muscle pain because of intramuscularly administration. Neurological and functional examinations, laboratory tests, electroencephalography, and magnetic resonance imaging were performed to assess safety of treatment. Mean FIM score increased by 20.88 ± 3.31 in the first month ( = 0.027) and by 31.38 ± 14.69 in 12 mo ( = 0.012). The rate of patients with an FIM score of 126 increased from 14.58% to 16.57% in the first month and 24.90% in 12 mo.
Multiple triple-route Wharton's jelly-derived MSC administrations were found to be safe for HIE patients, indicating neurological and functional improvement. Based on the findings obtained here, further randomized and placebo research could be performed.
缺氧缺血性脑病(HIE)是成人和新生儿发病及死亡的主要原因,治疗选择有限且功能障碍严重。
研究异基因间充质干细胞(MSCs)治疗HIE患者的安全性和初步疗效。
纳入患有HIE至少6个月且伴有明显功能障碍和残疾的患者。所有患者每月接受两次来自脐带华通氏胶的MSCs,剂量为1×10/kg,通过鞘内、静脉和肌肉注射,共持续两个月。通过多次随访评估MSCs的治疗效果和预后意义。采用功能独立性测量(FIM)、改良Ashworth量表和卡氏量表评估副作用、神经和认知功能以及总体结果。
研究纳入的8名受试者平均年龄为33.25±10.18岁。平均HIE暴露时间和HIE后平均持续时间分别为45.63±10.18个月和19.67±29.04个月。平均FIM评分为18.38±1.06,平均改良Ashworth评分为43.5±4.63,平均卡氏评分为20。在最初的24小时内,5名患者出现低热状态,鞘内注射导致轻度头痛,肌肉注射引起肌肉疼痛。进行神经和功能检查、实验室检查、脑电图和磁共振成像以评估治疗安全性。第一个月平均FIM评分增加20.88±3.31(P = 0.027),12个月时增加31.38±14.69(P = 0.012)。FIM评分≥126的患者比例在第一个月从14.58%增加到16.57%,12个月时为24.90%。
发现多次经三种途径给予来自脐带华通氏胶的MSCs对HIE患者是安全的,表明神经和功能有所改善。基于此处获得的结果,可进行进一步的随机和安慰剂研究。